In the last week, the market has stayed flat, yet over the past 12 months, it has risen by 19%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks that align well with these positive market conditions can be crucial for investors seeking potential opportunities in August 2026.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	21.54%	21.27%	★★★★★★
Fabrinet	20.12%	22.27%	★★★★★★
Coherent	29.33%	41.75%	★★★★★★
Lumentum Holdings	40.65%	104.45%	★★★★★★
Marker Therapeutics	67.79%	25.34%	★★★★★★
Insmed	32.21%	66.88%	★★★★★★
Madrigal Pharmaceuticals	27.97%	63.67%	★★★★★★
Syndax Pharmaceuticals	29.10%	69.45%	★★★★★★
Travere Therapeutics	24.05%	53.11%	★★★★★★
Precigen	34.82%	55.42%	★★★★★★

Let's dive into some prime choices out of from the screener.

Travere Therapeutics (TVTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $5.86 billion.

Operations: The company generates revenue primarily from the development and commercialization of innovative therapies, amounting to $591.33 million.

Travere Therapeutics, despite its unprofitability, is navigating a promising trajectory with a 24% annual revenue growth outpacing the US market average of 13%. The company's strategic focus on innovative treatments like FILSPARI in the nephrology space underscores its commitment to addressing complex medical needs. Recent earnings reflect a substantial increase in revenue to $169.58 million for Q2 2026 from $114.45 million the previous year, although net losses expanded due to intensified R&D efforts and operational expansions aimed at future profitability. This approach, coupled with robust projected earnings growth of 53.1% annually and an anticipated Return on Equity of 138.9%, positions Travere as a dynamic player within biotech, albeit with financial volatility as it scales operations and navigates regulatory landscapes.

AnaptysBio (ANAB)

Simply Wall St Growth Rating: ★★★★★★

Overview: AnaptysBio, Inc. is a clinical-stage biotechnology company that specializes in developing immunology therapeutics for autoimmune and inflammatory diseases in the United States, with a market capitalization of approximately $1.73 billion.

Operations: The company operates in the biotechnology sector, focusing on developing therapeutics for autoimmune and inflammatory diseases. As a clinical-stage entity, it does not generate revenue from product sales yet.

AnaptysBio, navigating through a challenging phase marked by recent exits from several Russell indexes, remains focused on strategic growth through innovative biotech developments. Despite being unprofitable currently, the company is poised for significant advancements with projected annual revenue growth at 20.5% and an anticipated shift to profitability within three years. This transition is supported by robust R&D investments aimed at fostering high-potential biotechnological innovations. Moreover, AnaptysBio's recent sublease agreement with First Tracks Biotherapeutics underscores a tactical approach to asset management, optimizing operational space while potentially stabilizing cash flows during its critical growth phase.

Coherent (COHR)

Simply Wall St Growth Rating: ★★★★★★

Overview: Coherent Corp. is a global company that develops, manufactures, and markets lasers, transceivers, and other optical and optoelectronic devices with a market cap of $63.81 billion.

Operations: The company generates revenue primarily from its Industrial and Datacenter & Communications segments, with the latter contributing $5.32 billion.

Coherent Corp. has demonstrated robust financial and operational growth, with a notable 41.8% projected annual earnings increase and a 29.3% rise in revenue expectations, outpacing the US market average significantly. The company's recent transition to profitability is underscored by its strategic R&D investments, which have not only enhanced product innovation but also positioned it effectively within the high-growth sectors of AI and high-performance computing. Recent developments include the launch of a 300mm silicon carbide substrate that addresses critical thermal management needs in AI systems, marking a significant step in Coherent’s commitment to advancing semiconductor technologies. This focus on high-value, scalable solutions is likely to sustain its growth trajectory well into the future.

Summing It All Up

• Reveal the 22 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.